Cardiometabolic Disease Risks Associated with Sleep Deficiency
How does insufficient sleep duration, irregular timed sleep schedules, and poor sleep quality contribute to the pathophysiology of lung, heart and blood diseases?
How does insufficient sleep duration, irregular timed sleep schedules, and poor sleep quality contribute to the pathophysiology of lung, heart and blood diseases?
What are informative and clinically relevant biomarkers of pulmonary hypertension (PH)?
Will sensitivity to the psychological aspects of obesity, including lifestyle priorities and motivations, improve the efficacy of long-term effectiveness of weight loss and obesity prevention interventions?
Goal 3: Advance Translational Research
Infrastructure for performing research in rare diseases should be enhanced to allow efficient accrual to multicenter trials.
What innovative methodologies applicable to small cohorts and rare outcomes can better ensure the success of clinical and implementation studies in the rare diseases affecting heart, lung, blood, and sleep?
Clinical trials are at a crossroads. They are too expensive, take too long, and often can't recruit adequately. A critical challenge is to develop tools that can change the cost, time, and recruiting practices for clinical trials.
Goal 3: Advance Translational Research
A critical challenge is the need to bring together basic behavioral scientists interested in understanding human behavior at a fundamental level, including how and why people become motivated and capable of undertaking behavioral changes, with clinical researchers interested in developing and testing new strategies for tackling resistant behavioral problems such as obesity and non-adherence.
Goal 4: Develop Workforce and Resources
Although the NCRR and NIGMS used to have a mechanism to train new generation of clinical & translational scientists, this program was stopped. Why?
What is the possibility of other institutes to come up with the priority of funding resources in this regard?
Goal 3: Advance Translational Research
Goal 3: Advance Translational Research
What structural changes need to be implemented in the health-care community in order to support the use of genomic information in clinical trials and drug development for hematologic diseases?
Are the current methodologies for clinical trials still the best practices for conducting efficient clinical trials?